Background: In the CHAMPION PHOENIX trial, compared with clopidogrel, cangrelor was shown to significantly reduce the primary composite endpoint of death, myocardial infarction (MI), ischemia driven revascularization (IDR), or stent thrombosis (ST) at 48 hours, as well as the secondary endpoint of ST. Protocol ST included intraprocedural ST (IPST) and Academic Research Consortium (ARC) defined ST. To examine the robustness of the effect of cangrelor on ischemic events, we performed sequential sensitivity analyses of the primary composite endpoint by excluding IPST and applying increasingly stringent criteria of MI. Methods: A total of 10,942 patients undergoing PCI for elective, urgent, or emergent indications were randomized to intravenous cangrelor bolus and infusion or to clopidogrel loading in the catheterization laboratory. Sensitivity analyses were performed examining progressively more restrictive definitions of MI and ST. Ischemic endpoints were adjudicated in a blinded fashion. Results: The Table lists sensitivity analyses of various composite efficacy endpoints at 48 hours in the modified intent-to-treat (mITT) population. There was a consistent risk reduction with cangrelor irrespective of the exact composite outcome examined. Specifically for MI, even when all biomarker defined MI were excluded, the treatment effect of cangrelor remained significant (death, MI only with symptoms or ischemic ECG changes, IDR, or ARC-ST; odds ratio 0.66, p¼0.003).
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Conclusions: Compared with clopidogrel, cangrelor reduces important ischemic events, even using the most restrictive definitions of MI and ST. Background: Increasing HbA1c portends an adverse cardiovascular prognosis. However, the association between glycemic control, platelet reactivity, and outcomes after PCI with drug-eluting stents (DES) is unknown. Methods: In the prospective multicenter ADAPT-DES registry, HbA1c levels were measured in 1,145/8,582 enrolled patients. We stratified patients by HbA1c < 6.5% (n¼547, 47.8%), 6.5-8.5% (n¼422, 36.8%) and >8.5% (n¼176, 15.4%). Platelet reactivity was assessed post-PCI with the VerifyNow system after aspirin and clopidogrel loading. High platelet reactivity (HPR) on clopidogrel was defined as P2Y12 reaction units (PRU) >208. Results: Patients with HbA1c >8.5% were younger, more likely female and nonCaucasian, had a higher BMI, and more insulin-treated diabetes and acute coronary syndromes. Hypertension, coronary artery disease, heart failure and renal insufficiency were less present when HbA1c was < 6.5%. HPR and stent thrombosis (ST) increased with greater HbA1c (Figure) . 
Conclusions:
In this large-scale study, the association between HbA1c and HPR was driven by comorbidities associated with poor glycemic control. Nonetheless, greater HbA1c independently predicted ST after PCI, warranting efforts to improve glycemic control after DES in diabetic patients.
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